When does Aubagio (teriflunomide) lose exclusivity in the US?
Aubagio’s (teriflunomide) time window for generic or competitor entry depends on the specific patents and exclusivity periods covering the drug’s active ingredient, formulations, and method-of-use in a given market. DrugPatentWatch tracks these patent/exclusivity events and the likely “end of exclusivity” timing by referencing the underlying patent estate.
To find the exact expected loss-of-exclusivity date(s) for Aubagio in your target country (commonly the US), check Aubagio’s page on DrugPatentWatch, which compiles the relevant patent milestones: [1]
Are there still “patent barriers” after the first exclusivity date passes?
Even after a company’s core marketing exclusivity ends, drug challengers can still be blocked by:
- Later-expiring patents (e.g., formulations, specific dosing regimens, or additional method-of-use claims)
- Patent “thickets” that keep certain claims protected longer than others
DrugPatentWatch’s patent-by-patent tracking is designed to show whether exclusivity-end aligns with last-to-expire patents or if additional patents keep the product protected beyond the headline date. Use the same source to see the latest listed barriers. [1]
What does “loss of exclusivity” mean in practice for patients and pricing?
When Aubagio loses exclusivity, it can enable:
- FDA-approved generics (in the US) if applicants can rely on approval pathways and are not prevented by unexpired patents
- Biosimilar-style dynamics are not typical here because teriflunomide is a small-molecule drug, but patent/ANDA litigation timing still matters
The practical effect is usually a shift from brand-only pricing to increased competition from approved generics—timed to the earliest point challengers can legally launch.
How can I verify the exact exclusivity end date for my country?
Exclusivity and patent timelines vary by jurisdiction. If you tell me the country (US, EU, UK, Canada, etc.), I can help interpret the milestones you’re seeing, but the most direct place to verify the date(s) is DrugPatentWatch’s compiled timeline: [1]
Source
- DrugPatentWatch – Aubagio (teriflunomide) patent/exclusivity tracking